Obermatt
See Similar Stocks →

Neurocrine Biosciences

NSQ:NBIX · US64125C1099
BiotechnologyLarge

360

95
EV / EBIT57
Price / Owner Earnings18
Owner Earnings Yield88
Dividend Yield1
Price/Sales76
EV / Gross Profit67
Price/Book53
Return on Capital94
Cash Return on Capital87
Return on Equity87
EBIT Margin71
Gross Profitability81
Cash Conversion54
Accruals29
Owner Earnings Margin76
Sales growth49
Profit Growth91
Long-Term EPS Growth90
Owner Earnings Growth89
Reinvestment31
Price momentum42
Debt load52
Refinancing82
Debt Payback100
Liquidity—
Analyst ratings44
Opinion Changes70
Price Target Upside27
Market mood72
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Neurocrine Biosciences generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeLarge
TypePublic Company
ExchangeNASDAQGS
Founded1992
Employees2,035
Websiteneurocrine.com
ISINUS64125C1099
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)S&P MIDCAP (USA)D.J. US Health Care
Themes
NeurologyObesityEndocrinologyPsychiatryNeuroscienceCentral Nervous SystemBiotechnologyHealth CarePharmaceutical

Description

Neurocrine Biosciences, Inc. (Neurocrine Biosciences) operates as a neuroscience-focused, biopharmaceutical company. The company is dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed…

Analysis

Quality compounder

Neurocrine Biosciences, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is fair. You pay 24.5× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 9% yearly growth; analysts expect 43%. The price, in other words, assumes less than the experts do.

The trajectory is solid and the balance sheet is sturdy. The company scores 20/20 on our value-creation score: strong value creator.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Similar Stocks

The companies this stock is ranked against.

Compare Neurocrine Biosciences with its peers
Bright Minds Biosciences
CNX:DRUG
88
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Xenon Pharmaceuticals
NMQ:XENE
28
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Ardelyx
NMQ:ARDX
82
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Cytokinetics
NSQ:CYTK
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vir Biotechnology
NSQ:VIR
56
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Biogen Idec
NSQ:BIIB
82
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →